Moderna, Inc. Common Stock MRNA
$174.38
+176.97%
at last close
Market Cap$25.14 billion
P/E Ratio—
Div Yield—
Volume199.31M
52-Week Range
$22.28$176.66
Analyst Ratings
- Consensus
- Hold — 2 Buy · 9 Hold · 3 Sell (14 analysts)
- Avg. Price Target
- $45.17 (-74.1% downside)
Key Stats
- Today's Range
- $114.46 – $176.66
- 50-Day Range
- $45.40 – $176.66
- 52-Week Range
- $22.28 – $176.66
- Volume
- 199.31 million shs
- Average Volume
- 11.92 million shs
- Market Cap
- $25.14 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.72
- Price / Sales
- 11.28
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 2.56
Financials (TTM)
- Revenue
- $2.23 billion
- Net Income
- $-3,151,000,000
- Net Margin
- -141.43%
- Return on Equity
- -46.61%
- Debt-to-Equity
- —
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Related Stocks
Compare head-to-head: MRNA vs AMGN·MRNA vs HALO·MRNA vs KYMR·MRNA vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.